Cargando…

Challenges in severe asthma: Do we need new drugs or new biomarkers?

Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Adatia, Adil, Vliagoftis, Harissios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550875/
https://www.ncbi.nlm.nih.gov/pubmed/36237537
http://dx.doi.org/10.3389/fmed.2022.921967
_version_ 1784805980823879680
author Adatia, Adil
Vliagoftis, Harissios
author_facet Adatia, Adil
Vliagoftis, Harissios
author_sort Adatia, Adil
collection PubMed
description Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future.
format Online
Article
Text
id pubmed-9550875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95508752022-10-12 Challenges in severe asthma: Do we need new drugs or new biomarkers? Adatia, Adil Vliagoftis, Harissios Front Med (Lausanne) Medicine Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biologicals, leading to significant interest in biomarkers to guide treatment. Some severe asthmatics remain suboptimally controlled despite trials of biologicals and many of these patients still require chronic systemic corticosteroids. New therapeutics are currently in development to address this unmet need. However, whether these patients could be better treated by using novel biomarkers that inform selection among currently available biologics, and that objectively measure disease control is unclear. In this review, we examine the currently used biomarkers that guide severe asthma management and emerging biomarkers that may improve asthma therapy in the future. Frontiers Media S.A. 2022-09-27 /pmc/articles/PMC9550875/ /pubmed/36237537 http://dx.doi.org/10.3389/fmed.2022.921967 Text en Copyright © 2022 Adatia and Vliagoftis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Adatia, Adil
Vliagoftis, Harissios
Challenges in severe asthma: Do we need new drugs or new biomarkers?
title Challenges in severe asthma: Do we need new drugs or new biomarkers?
title_full Challenges in severe asthma: Do we need new drugs or new biomarkers?
title_fullStr Challenges in severe asthma: Do we need new drugs or new biomarkers?
title_full_unstemmed Challenges in severe asthma: Do we need new drugs or new biomarkers?
title_short Challenges in severe asthma: Do we need new drugs or new biomarkers?
title_sort challenges in severe asthma: do we need new drugs or new biomarkers?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550875/
https://www.ncbi.nlm.nih.gov/pubmed/36237537
http://dx.doi.org/10.3389/fmed.2022.921967
work_keys_str_mv AT adatiaadil challengesinsevereasthmadoweneednewdrugsornewbiomarkers
AT vliagoftisharissios challengesinsevereasthmadoweneednewdrugsornewbiomarkers